ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
44 announcements with these filters
Dr. Agarwal's Health Care submitted ICRA's monitoring agency report for the quarter ended September 30, 2026. ICRA reports no material deviation in IPO proceeds utilisation.
Dr. Agarwal's Health Care allotted 54,728 equity shares to employees on exercise of ESOP 2022 options. Paid-up capital rose to 31,70,99,111 shares, with no cash consideration stated.
Q2 FY27 revenue ₹655 Cr (+31.4% YoY) and PAT ₹57 Cr (+55.8%), network-led growth; India EBITDA margin flat near 28%.
Dr Agarwals Health Care reports Mr. Amar Agarwal's redesignation from Chairman and Non-Executive Director to Executive Director, effective 1 November 2026. The change was approved at a board meeting held on 5 November 2026.
Q2 FY27 revenue ₹655 Cr (+31.4% YoY) and PAT ₹57 Cr (+55.8%). H1 FY27 revenue ₹1,269 Cr (+28.7%), PAT ₹112 Cr (+50.1%). Strategy is aggressive facility expansion, with 65 FY27E additions.
Dr. Agarwal's H1 FY27 revenue rose 28.7% to Rs 1,269 crore; PAT rose 50.1% to Rs 112 crore. Amar Agarwal's executive chairman appointment awaits postal ballot approval.
Dr. Agarwal's Health Care schedules a board meeting on November 5, 2026 to consider Q2 results. An earnings call follows at 6:30 PM IST that day.
Dr. Agarwals Health Care Limited has completed the merger of Dr. Agarwal's Eye Hospital Limited into itself for a total transaction value of ₹711.21 Crore.
Dr. Agarwal's Health Care Limited allotted 18,200 equity shares upon the exercise of vested ESOPs. The transaction is valued at approximately ₹0.24 Crore.
The amalgamation scheme between Dr. Agarwal's Health Care and Dr. Agarwal's Eye Hospital is effective from November 01, 2026. The Record Date is November 18, 2026.
Dr. Agarwals Health Care Ltd has submitted its quarterly shareholding pattern statement for the quarter ended September 30, 2026, pursuant to SEBI Regulation 31(1)(b).
Dr. Agarwal's Health Care Ltd. completed the acquisition of its Nigeria-based step-down wholly owned subsidiary, previously announced on August 4, 2026, for ₹0.73 Crore.
Dr. Agarwal's Health Care Limited confirmed that its step-down subsidiary, Orbit Healthcare Services Nigeria Ltd., is now a wholly owned subsidiary of Orbit Mauritius.
Mr. Sanjay Anand has ceased to be an Independent Director of Dr. Agarwal's Health Care Limited upon completion of his tenure, effective September 29, 2026.
Dr. Agarwal's Health Care Limited held its 16th AGM on September 21, 2026. Shareholders approved all agenda items, including financial statements and director re-appointments.
Dr. Agarwal's Health Care Limited has issued the notice for its Sixteenth Annual General Meeting, scheduled for September 21, 2026, alongside its FY 2025-26 Annual Report.
Dr. Agarwals Eye Hospital, a subsidiary, launched the World's First Pinhole Pupilloplasty Centre in Chennai. This facility advances specialized surgical treatments for complex corneal disorders.
Catalyst Trusteeship Limited reported the creation of a pledge over 7,538,303 equity shares of Dr. Agarwal's Health Care Limited, representing 2.38% of its capital.
DB International Trust disclosed a partial release of pledge and disposal of 24,160,000 shares in Dr. Agarwal’s Health Care Ltd. The disclosure complies with Reg 29(2).
Catalyst Trusteeship Limited reported a release of pledge over 3,16,98,303 equity shares of Dr. Agarwal's Health Care Limited. The transaction pertains to a USD 100 million facility.
ICICI Prudential Mutual Fund acquired 1,69,99,999 shares of Dr. Agarwal's Health Care Limited through the open market. This acquisition represents a 5.36% stake in the company.
Dr. Agarwals Health Care will incorporate a new subsidiary, Orbit Health Care Services (Nigeria) Ltd, for Rs.0.70 Crore. This investment supports its Nigerian eye care expansion.
Dr Agarwals Health Care has appointed S.R. Batliboi & Associates LLP as statutory auditor, KPMG as internal auditor, and re-appointed B Y & Associates as cost auditor.
Dr. Agarwal's Health Care Ltd appointed S.R. Batliboi & Associates as Statutory Auditor, KPMG as Internal Auditor, and re-appointed B Y & Associates as Cost Auditor.
Dr. Agarwal’s reported strong Q1FY27 results with revenue of ₹614 Cr and EBITDA of ₹177 Cr. Strategy focuses on aggressive 'Greenfield' expansion and hub-and-spoke scalability across India and Africa.
Dr. Agarwals Health Care Ltd reported revenue from operations of ₹614 Cr (+26.0% YoY) and net profit of ₹55 Cr (+44.4% YoY) for Q1 FY27.
Dr. Agarwal's Health Care Ltd will hold a board meeting on August 4, 2026, to approve financial results and host an earnings conference call.
Dr Agarwals Health Care allotted 43,155 equity shares under its ESOP/ESPS scheme. Post-allotment, the company's paid-up share capital increased to Rs 31,70,26,183.
Dr. Agarwal's Health Care allotted 43,155 equity shares under its 2022 ESOP scheme. Total paid-up capital increased to Rs.31.70 Crore following this allotment.
Dr. Agarwal's Eye Institute clarified SBO details for shareholding pattern, noting PAN and nationality for Dr. Adil Agarwal only. No financial impact is associated with the update.